Diehl 2013

Methods	Individual randomised controlled trials
Participants	Inclusion criteria: patients older than 18 years with facial seborrhoeic dermatitis, diagnosis confirmed by investigator that they were not on any treatment that could interfere with test products Exclusion criteria: pregnant women, immunocompromised persons, patients with previous history of cancer Age: QX (15.7 ± 6.99), 2% keto (14.64 ± 8.33) Sex, M:F: QX (9:11), 2% keto (10:10)
Interventions	Intervention: aqueous gel containing 4% extract of Quassia amara applied twice a day to the face for 28 days (n = 20) Control 1: ketoconazole 2% gel applied similarly (n = 20) Control 2: ciclopirox olamine 1% gel applied similarly (n = 20)
Outcomes	Complete remission as determined by the investigator
Notes	Country: Argentina; COI: no disclosure of COI
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Investigators used a tool, the Researcher Randomizer, version 3.0; http:.//www.randomizer.org
Allocation concealment (selection bias)	Unclear risk	"randomized double blind study"
Baseline comparable?	Low risk	Ketoconazole patients on average 5 years older; gender, duration, previous treatment similar
Patient blinded?	Unclear risk	Not reported
Provider blinded?	Unclear risk	Not reported
Outcome assessor blinded?	Unclear risk	Not reported
Co-interventions avoided?	Low risk	No other treatment allowed
Compliance acceptable?	Unclear risk	Not reported
Drop-out acceptable?	Low risk	3/20 in ketoconazole group, 2/20 in Quassia group, 1/20 in ciclopirox group
Selective outcome reporting acceptable?	High risk	Table 4 is missing; not all remission categories reported
ITT?	Unclear risk	Not reported and unclear imputation for missing data